Form 144 Filer Information

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK	0001950499
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Acrivon Therapeutics, Inc.
SEC File Number	001-41551
Address of Issuer	c/o Acrivon Therapeutics, Inc. 480 Arsenal Way, Suite 100 Watertown MASSACHUSETTS 02472
Phone	617-207-8979
Name of Person for Whose Account the Securities are To Be Sold	Peter Blume-Jensen

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Services 200 W Civic Center Drive, 4th Floor Sandy UT 84070	1276	1824.68	42911680	11/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	11/14/2026	Settlement of vested RSUs issued under an S-8 Registration Plan	Issuer	☐		3756	11/14/2026	Equity compensation for services rendered

***** If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Peter Blume-Jensen 480 Arsenal Way Suite 100 Watertown MA 02472	Common Stock	08/18/2026	1229	2470.29
Kristina Masson 480 Arsenal Way Suite 100 Watertown MA 02472	Common Stock	08/18/2026	484	972.84
Peter Blume-Jensen 480 Arsenal Way Suite 100 Watertown MA 02472	Common Stock	08/25/2026	14036	30969.08

144: Remarks and Signature

Remarks	Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. These securities were sold by the Issuer's President and CEO, Dr. Peter Blume-Jensen. The table of securities sold during the past 3 months includes sales by each of Dr. Peter Blume-Jensen and his spouse, Dr. Kristina Masson, who is also a director and officer of the Issuer.
Date of Notice	11/17/2026

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Adam D. Levy, Attorney-in-Fact

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)